DAVID E. NICHOLS, PHD
GEORGE R. GREER, MD
MARK A. GEYER, PHD
ROLAND R. GRIFFITHS, PHD
CHARLES S. GROB, MD
DENNIS J. MCKENNA, PHD
STEPHEN ROSS, M.D.
FRANZ X. VOLLENWEIDER, MD
ROBERT J. BARNHART
ELIZABETH GORDON
WILLIAM A. LINTON
RICHARD M. WOLFE
divider
LYNETTE HERRING
Stephen Ross, M.D.
OUR ADVISORY PANEL arrow
OUR RESEARCH arrow

Stephen Ross, M.D.

divider

Board Member

Stephen Ross, M.D., is Associate Professor of Psychiatry and Child & Adolescent Psychiatry at the New York University (NYU) School of Medicine and Associate Professor of Oral and Maxillofacial Pathology, Radiology and Medicine at the NYU College of Dentistry. He directs the Division of Alcoholism and Drug Abuse, the Dual Diagnosis Training Unit and the Opioid Overdose Prevention Program at Bellevue Hospital Center in New York City. He is the Clinical Director of the NYU Langone Center of Excellence on Addiction and Director of the NYU Addiction Psychiatry Fellowship. Dr. Ross received his undergraduate degree from the University of Pennsylvania graduating phi beta kappa, summa cum laude and majoring in the biological basis of behavior. He received his MD from the UCLA School of Medicine, completed his residency in General Psychiatry at Columbia University/New York State Psychiatric Institute and fellowship in Addiction Psychiatry at New York University/Bellevue Hospital. He is certified in General and Addiction Psychiatry from the American Board of Psychiatry and Neurology (ABPN) and in Addiction Medicine by the American Society of Addiction Medicine (ASAM). Dr. Ross has received 9 teaching awards related to education of medical students, psychiatry residents, and post-graduate fellows- locally at NYU and nationally.  His research interests revolve around exploring novel diagnostic and treatment approaches to addictive spectrum illnesses and psychological distress in patients with advanced or terminal cancer. Active projects include: Neurokinin 1 antagonist effects and neuro-economic paradigm testing in intravenous heroin dependence (supported by NIDA); Cocaine Use Reduction Buprenorphine (CURB) NIDA Clinical Trials Network (CTN 0048); Genetic and Psychosocial Determinants of Prescription Opioid Dependence (research collaborative with the Geisinger Health System and NYU/Bellevue Hospital); Novel Treatment Approaches for Dually Diagnosed Adolescent Inpatients (Bellevue Hospital); Naloxone Distribution Opioid Overdose Prevention Program (Bellevue Hospital). Dr. Ross is an expert on the therapeutic application of serotonergic hallucinogens to treat psychiatric and addictive spectrum illnesses. He directs the NYU Psychedelic Research Group and is Principal Investigator of the NYU Psilocybin Cancer Project. Future projects include: psilocybin-assisted psychotherapy to treat alcohol use disorders; psilocybin-assisted spiritual enhancement; NYU Psychedelic Psychotherapy Training Program. Dr. Ross receives his research funding from the National Institute on Drug Abuse and the Heffter Research Institute.

Bibliography

Ross S. Motivation and Change in Co-occurring Disorders in Handbook of Motivation and Change: A Practical Guide for Clinicians- 1st ed. Editors: Levounis P and Arnout B. The American Psychiatric Publishing. 2010; 129-148.

Ross S, Peselow E. The Neurobiology of Addictive Disorders. Clinical Neuropharmacology. 2009;32(5):269-276.

Ross S, Peselow E. Pharmacotherapies for Addictive Disorders. Clinical Neuropharmacology. 2009;32(5): 277-289.

Cheney B, Galanter M, Dermatis H, Ross S. Medical versus Spiritual Orientations: Differential Patient Views toward Recovery. The American Journal of Drug and Alcohol Abuse. 2009;35:301-304.

Ross S. Ketamine and Addiction. Primary Psychiatry. 2008;15(9):61-69

Ross S, Fallon BA, Petkova E. Feinstein S, Liebowitz MR. Long-Term follow-up study of patients with refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2008;20(4):450-7.

Ross S. The Mentally Ill Substance Abuser. Textbook of Substance Abuse Treatment, 4th edition. Editors: Galanter M, and Kleber M. The American Psychiatric Publishing. 2008; 537-554.

Ross S, Cidambi I, Dermatis H, Weinstein J, Ziedonis D, Roth S, Galanter M. Music Therapy: A Novel Motivational Approach for Dually Diagnosed Patients. Journal of Addictive Diseases. 2008;27(1):41-53.

Castaneda R, Levy R, Hazzi C, Ross S, Roman W, Hamid H. Treating adult attention deficit hyperactivity disorder in hospitalized psychiatric patients. General Hospital Psychiatry. 2008;30:572-577.

Ross S. Overcoming Crystal Meth Addiction: Review. Journal of Addictive Diseases. 2007;26(2):93-94.

Grodzicki, J, Ross, S, Galanter, M. A model for substance abuse consultation in a general hospital: Process and outcome. American Journal on Addictions. 2006; 15: 324

Paizis M, Ross S, Dermatis H. Issues in Treating Patients with Combined Substance Abuse and Axes I and II General Psychiatric Disorders. Substance Abuse. 2006;26(1):43-4.

Ross S, Collins E, Galanter M. Substance Abuse in the Medically Ill. In: Blumenfeld M, Strain J, eds, Psychosomatic Medicine, Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 461-492.

Ross S. The Group Therapy of Substance Abuse. The Journal of the Eastern Group Psychotherapy Society. 2006;30.1: 65-69.

Ross S. Alcohol Use Disorders: Special Topics. Guest Editor's Notes. Primary Psychiatry. 2005;12(1):30-31.

Ross S. Alcohol Use Disorders in the Elderly. Primary Psychiatry. 2005;12(1):32-40.

Ross S, Hayden F. Study Guide to Textbook of Substance Abuse Treatment, 3rd edition. Editors: Galanter M, and Kleber M, 2005.

Ross, S. Virtual Mentor: Identifying an Impaired Physician. Ethics Journal of the American Medical Association. 2003; 5(12).

Ross S, Galanter M. Consultation-Liaison Psychiatry Literature Database (2003 Update). Substance Abuse. General Hospital Psychiatry. 2003;25(6): 464-465

Ross S, Dermatis, H, Levounis P, and Galanter M. A Comparison between Dually Diagnosed Inpatients with and without Axis II Co-morbidity and the Relationship to Treatment Outcome. The American Journal of Drug and Alcohol Abuse. 2003;29(2):263-279.